Cancer Research SABCS  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 68, 1251, March 1, 2008. doi: 10.1158/0008-5472.CAN-07-5983
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ray, D.
Right arrow Articles by Kiyokawa, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ray, D.
Right arrow Articles by Kiyokawa, H.

Reviews

CDC25A Phosphatase: a Rate-Limiting Oncogene That Determines Genomic Stability

Dipankar Ray and Hiroaki Kiyokawa

Department of Molecular Pharmacology and Biological Chemistry, and Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois

Requests for reprints: Hiroaki Kiyokawa, Department of Molecular Pharmacology and Biological Chemistry, Northwestern University, 303 E. Superior Street, Lurie 3-113, Chicago, IL 60611. Phone: 312-503-0699; Fax: 312-503-0700; E-mail: kiyokawa{at}northwestern.edu.

Key Words: breast cancer • cell cycle • checkpoint • knockout mice • CHK1 • RAS • HER2/neu

CDC25A is a critical regulator of cell cycle progression and checkpoint response. Overexpression of this cyclin-dependent kinase phosphatase occurs often in human cancers. Our recent genetic studies in the mouse indicate that restricting CDC25A can limit tumorigenesis induced by the HER2/neu-RAS oncogenic pathway without compromising normal cell division or viability. These findings offer a sound foundation to justify development of CDC25A inhibitors for antitumor therapy. [Cancer Res 2008;68(5):1251–3]




This article has been cited by other articles:


Home page
Cancer Res.Home page
P. Wang, F. Zou, X. Zhang, H. Li, A. Dulak, R. J. Tomko Jr., J. S. Lazo, Z. Wang, L. Zhang, and J. Yu
microRNA-21 Negatively Regulates Cdc25A and Cell Cycle Progression in Colon Cancer Cells
Cancer Res., October 15, 2009; 69(20): 8157 - 8165.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
S. Madlener, M. Rosner, S. Krieger, B. Giessrigl, M. Gridling, T. P. N. Vo, C. Leisser, A. Lackner, I. Raab, M. Grusch, et al.
Short 42{degrees}C heat shock induces phosphorylation and degradation of Cdc25A which depends on p38MAPK, Chk2 and 14.3.3
Hum. Mol. Genet., June 1, 2009; 18(11): 1990 - 2000.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.